Bal Pharma: Should You Buy, Hold, or Sell Right Now?
- September 8, 2026
- Posted by: Lakshit Sharma
- Category: Market
Bal Pharma share price Rs 96 (NSE), up over 3.5% today, near its 52-week high. 52-week range Rs 59.69 to Rs 99. Q1 FY27 profit up sharply YoY despite a dip from the prior quarter.
Quick Answer
Bal Pharma Ltd share price is trading around Rs 96, up more than 3.5 percent today, close to its 52-week high of Rs 99 and more than 60 percent above its 52-week low of Rs 59.69. Q1 FY27 revenue grew 33.7 percent year on year to Rs 89.06 crore, with net profit surging to Rs 1.14 crore from Rs 0.21 crore, though down from a stronger Rs 3.60 crore profit in the March 2026 quarter, part of an otherwise consistent improving trend across the year. Full-year FY25 revenue fell 10.8 percent to Rs 305.29 crore, with profit roughly flat at Rs 7.24 crore versus Rs 7.45 crore in FY24. The stock trades at a discount of 20.40 times earnings against the pharmaceutical sector average near 37.7 times.
Bal Pharma share price is up more than 3.5 percent today, trading around Rs 96 on the NSE, close to its 52-week high of Rs 99, more than 60 percent above its 52-week low of Rs 59.69. With a strong year-on-year improvement in Q1 FY27 despite a dip from the preceding quarter, investors are asking whether this pharmaceutical formulations manufacturer is a stock to buy near its highs, a hold, or a sell.
This Bal Pharma stock analysis walks through the Q1 FY27 numbers, the improving quarterly trend through the year, valuation against the pharmaceutical sector, shareholding pattern and the technical setup, using figures sourced from public filings.
Click Here – Get Free Investment Predictions
About Bal Pharma
Before deciding on Bal Pharma share price, it helps to understand the underlying business. Bal Pharma Ltd. manufactures pharmaceutical formulations and active pharmaceutical ingredients, serving domestic and export markets.
As a pharmaceutical formulations manufacturer, Bal Pharma has shown a broadly improving quarterly profit trend across the past year, rising from Rs 0.21 crore to a peak of Rs 3.60 crore in March 2026, before the most recent quarter dipped to Rs 1.14 crore, still well above the year-ago level.
Bal Pharma Share Price Today: Key Levels
The table below summarises where Bal Pharma share price stands right now against its recent trading range and market value.
| Metric | Value |
|---|---|
| Bal Pharma CMP (NSE) | Rs 96.00 |
| Bal Pharma CMP (BSE) | Rs 96.00 |
| 52-Week High | Rs 99.00 |
| 52-Week Low | Rs 59.69 |
| Market Capitalisation | Approximately Rs 148 crore |
| Dividend Yield | 1.29% |
Bal Pharma share price is up today and trading close to its 52-week high, having risen more than 60 percent from its 52-week low, reflecting investor confidence in the broadly improving trend.
Check the Univest Screener for Live Stock Data
Bal Pharma Financial Performance
The Bal Pharma share price trend is closely tied to how these numbers evolve each quarter. Bal Pharma reported Q1 FY27 (June 2026 quarter) revenue of Rs 89.06 crore, up 33.7 percent year on year from Rs 66.59 crore, with net profit surging to Rs 1.14 crore from Rs 0.21 crore. While this was down from a stronger Rs 3.60 crore profit in the March 2026 quarter, it remains part of a broadly improving trend across the year: Rs 0.21 crore, Rs 0.72 crore, Rs 1.79 crore, Rs 3.60 crore, and now Rs 1.14 crore.
For the full year FY25, the company reported revenue of Rs 305.29 crore, down 10.8 percent year on year from Rs 342.07 crore, with net profit roughly flat at Rs 7.24 crore versus Rs 7.45 crore in FY24, showing the annual top line softened even as profitability held steady.
| Period | Revenue | Net Profit | Comment |
|---|---|---|---|
| Q1 FY27 (Jun 2026) | Rs 89.06 crore | Rs 1.14 crore | +33.7% revenue; profit up sharply YoY, though down from Mar 2026 peak |
| FY25 (full year) | Rs 305.29 crore | Rs 7.24 crore | Revenue -10.8%; profit roughly flat YoY |
Valuation Check: Is Bal Pharma Share Price Expensive?
Any view on Bal Pharma share price should start from these valuation multiples. Bal Pharma share price currently reflects a price to earnings ratio of about 20.40 times trailing earnings, a discount to the broader pharmaceutical sector average of roughly 37.7 times. The price to book ratio stands near 1.8 times, with return on equity at 7.64 percent.
Debt to equity of 1.94 is elevated. Given the broadly improving quarterly trend despite the recent dip from the March 2026 peak, this discount valuation could offer some room for re-rating if the improving trend resumes, though the elevated leverage warrants continued attention.
Technical Signals: What the Chart Shows
Price action here often foreshadows the next move in Bal Pharma share price. Bal Pharma share price is up more than 3.5 percent today, positioned close to its 52-week high of Rs 99, more than 60 percent above its 52-week low of Rs 59.69, reflecting a strong overall run over the past year. A stock trading this close to its high, backed by a broadly improving quarterly trend, typically signals the market rewarding tangible execution despite the most recent quarter’s dip from its peak.
Trading volumes remain heavy today, so investors should track Bal Pharma share price alongside confirmation that the improving trend resumes in coming quarters, rather than reading too much into a single day’s move at these technical levels.
Download the Univest iOS App or Univest Android App to track Bal Pharma’s live price and technical levels.
Shareholding Pattern
Shifts here can influence Bal Pharma share price more than headline news on some sessions. Bal Pharma is a promoter-led pharmaceutical formulations manufacturer with elevated leverage. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company’s latest exchange filing.
Why Investors Are Watching Bal Pharma
- Broadly improving quarterly trend: Profit has generally trended higher across the past year, from Rs 0.21 crore to a peak of Rs 3.60 crore, even with the most recent quarter’s dip.
- Discount valuation to sector: A 20.40x PE against a 37.7x pharmaceutical sector average offers some valuation cushion.
- Strong stock performance over the past year: The stock has risen more than 60 percent from its 52-week low, reflecting sustained investor confidence.
- Dividend-paying business: A dividend yield of 1.29 percent provides some income alongside the discount valuation.
Risks and Factors to Watch
- Elevated leverage: A debt to equity ratio of 1.94 adds meaningful financial risk.
- Recent dip from the March 2026 profit peak: Q1 FY27 profit fell from the stronger March 2026 quarter, and investors should watch for confirmation that the broader improving trend resumes rather than reverses.
- Softer FY25 annual revenue: Full-year FY25 revenue declined 10.8 percent year on year, even as profitability held roughly steady.
- Pharmaceutical formulations competitive market: Bal Pharma competes against numerous domestic and international pharmaceutical formulations manufacturers.
Bal Pharma Share Price Target: What the Data Suggests
Until then, Bal Pharma share price remains best tracked through live, verified data rather than a single fixed number. Bal Pharma does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. What the data shows is a company with a broadly improving quarterly trend, trading at a discount to the pharmaceutical sector.
Investors who want live, updated research can check the Univest Screener, and should consult a SEBI-registered investment adviser for guidance tailored to their own goals.
Bal Pharma: Should You Buy, Hold, or Sell Right Now?
This is the core question behind Bal Pharma share price right now. The Bal Pharma buy or sell decision depends on whether the broadly improving trend resumes after the recent dip.
The case for buying: Investors who believe the recent dip from the March 2026 peak is temporary and see the discount to sector PE as attractive may find the current level, near its 52-week high, worth considering.
The case for holding: Existing shareholders who already track Bal Pharma’s improving trend may prefer to stay invested.
The case for waiting: Investors wanting to see the improving trend clearly resume before committing fresh capital may prefer to wait for that confirmation.
Weigh this against your own risk tolerance and consult a SEBI-registered investment adviser if unsure.
Conclusion
Bal Pharma share price reflects a pharmaceutical formulations manufacturer with a broadly improving quarterly trend across the past year, even as the most recent quarter dipped from its March 2026 peak, trading close to its 52-week high at a discount to the pharmaceutical sector. This article is for informational purposes and not a personalised investment recommendation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Q1. Is Bal Pharma a good stock to buy right now?
Ans. Bal Pharma’s Q1 FY27 profit surged year on year to Rs 1.14 crore, part of a broadly improving trend across the year, even though it dipped from a stronger Rs 3.60 crore in the preceding quarter. The stock trades at a discount to the pharmaceutical sector.
Q2. Why did Bal Pharma’s share price rise today?
Ans. Bal Pharma share price rose more than 3.5 percent today, close to its 52-week high, reflecting continued investor confidence in the company’s broadly improving trend, though no specific additional catalyst was clearly identified in available disclosures.
Q3. What is the Bal Pharma share price today?
Ans. Bal Pharma share price is trading around Rs 96 on the NSE, close to its 52-week high of Rs 99. The stock’s 52-week low is Rs 59.69.
Q4. What is the Bal Pharma share price target?
Ans. Bal Pharma does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. Investors can check live research on the Univest Screener and consult a SEBI-registered adviser.
Q5. What does Bal Pharma manufacture?
Ans. Bal Pharma manufactures pharmaceutical formulations and active pharmaceutical ingredients, serving domestic and export markets.
Q6. What is Bal Pharma’s market capitalisation and PE ratio?
Ans. Bal Pharma has a market capitalisation of approximately Rs 148 crore and trades at a price to earnings ratio of about 20.40 times, a discount to the pharmaceutical sector average PE of roughly 37.7 times.